| Followers | 184 |
| Posts | 10548 |
| Boards Moderated | 0 |
| Alias Born | 11/23/2007 |
Thursday, October 01, 2020 11:17:29 PM
If you get the weekly scrips please post or message me.
If you haven't listened to the Sept 14th Investors Conference Call, I think it's worth a listen. It's on the Esperion Website: https://morganstanley.webcasts.com/viewer/event.jsp?ei=1362617&tp_key=0d55b82feb
Scripts are outpacing all PCSK9i's compared to the launch of those drugs with virtually NO advertising AND during a Pandemic! PCSK9i's are a billion dollar drug and Nexletol and Nexlezit will make them obsolete before long. CEO Mayleben says as much on the Investor CC.
I think there's a good chance for atleast a 50% gain from these level prior to the end of the year.
Mark this post!
All the best
If you haven't listened to the Sept 14th Investors Conference Call, I think it's worth a listen. It's on the Esperion Website: https://morganstanley.webcasts.com/viewer/event.jsp?ei=1362617&tp_key=0d55b82feb
Scripts are outpacing all PCSK9i's compared to the launch of those drugs with virtually NO advertising AND during a Pandemic! PCSK9i's are a billion dollar drug and Nexletol and Nexlezit will make them obsolete before long. CEO Mayleben says as much on the Investor CC.
I think there's a good chance for atleast a 50% gain from these level prior to the end of the year.
Mark this post!
All the best
Recent ESPR News
- Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 • GlobeNewswire Inc. • 05/26/2026 12:00:00 PM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/14/2026 08:30:00 PM
- Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 • GlobeNewswire Inc. • 05/13/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:10:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/04/2026 08:05:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/01/2026 08:00:21 PM
- Esperion to be Acquired by ARCHIMED • GlobeNewswire Inc. • 05/01/2026 11:00:00 AM
- Esperion to Report First Quarter 2026 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 08:12:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 08:11:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:22:14 PM
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) • GlobeNewswire Inc. • 04/02/2026 08:00:00 PM
- Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:12:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:19:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:17:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:12:41 PM
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session • GlobeNewswire Inc. • 03/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 08:20:52 PM
- Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia • GlobeNewswire Inc. • 03/16/2026 10:30:00 AM
- Esperion shares rise 8% after revenue tops forecasts and acquisition announced • IH Market News • 03/10/2026 12:56:39 PM
